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Introduction: Non–small-cell lung cancer (NSCLC) is an aggres-
sive, highly chemoresistant disease. Reliable prognostic assays and 
more effective treatments are critically required. BIRC6 (baculovi-
ral inhibitors of apoptosis proteins repeat-containing 6) protein is a 
member of the inhibitors of apoptosis protein family thought to play 
an important role in the progression or chemoresistance of many 
cancers. In this study, we investigated whether BIRC6 expression 
can be used as a prognostic marker or potential therapeutic target 
for NSCLC.
Methods: In a retrospective analysis, BIRC6 protein expression was 
determined for 78 resected primary NSCLCs and nine benign lung 
tissues. Twenty-nine chemoresistant or chemosensitive subrenal cap-
sule NSCLC tissue xenografts were assessed for BIRC6 expression, 
using immunohistochemistry, and 13 of them for BIRC6 gene copy 
number, using array comparative genomic hybridization analysis. 
The effect of small interfering RNA–induced BIRC6 knockdown on 
the growth of human NSCLC cell cultures and apoptosis (in combi-
nation with cisplatin) was investigated.
Results: Elevated BIRC6 protein expression in NSCLC tissues was 
associated with poor 3-year relapse-free patient survival, lymph node 
involvement, and advanced pathological tumor, node, metastasis 
stage. In patient-derived lung squamous cell carcinoma xenografts, 
chemoresistance was associated with elevated BIRC6 expression and 
increased gene copy number. Small interfering RNA–induced BIRC6 
down-regulation inhibited growth of the NSCLC cells and sensitized 
the cells to cisplatin.
Conclusions: BIRC6 may play an important role in the malignant 
progression and chemoresistance of NSCLC. Elevated BIRC6 pro-
tein expression may serve as a predictive marker for chemoresistance 
of NSCLCs and a poor prognostic factor for NSCLC patients. Down-
regulation of the BIRC6 gene as a therapeutic approach may be effec-
tive, especially in combination with conventional chemotherapeutics.
Key Words: Baculoviral inhibitors of apoptosis proteins repeat-con-
taining 6, Prognostic factor, Non–small-cell lung cancer, Recurrence, 
Patient survival, Chemoresistance.
(J Thorac Oncol. 2013;8: 161–170)
Lung cancer is the most common cause of cancer-related deaths in both developing and developed countries, lead-
ing to more than 1.1 million deaths worldwide in 2008.1 
Approximately 85% of all lung cancer cases are non–small-
cell lung cancers (NSCLC).2,3 Despite progress in the diagno-
sis and treatment of NSCLC, patient survival is poor (~15% at 
5 years).4,5 Even in the case of surgically resectable stage I–III 
NSCLCs, approximately 50% of patients die within 5 years. In 
general, NSCLCs are highly chemoresistant, and postoperative 
conventional chemotherapy has only a marginal benefit, ren-
dering an absolute improvement of 4% in survival at 5 years.6
Chemoresistance of cancers, including NSCLCs, is 
thought to be primarily due to resistance to drug-induced apop-
tosis, and overcoming such a hurdle represents an important 
strategy for cancer therapy.7 Resistance to apoptosis is thought 
to occur through up-regulation of antiapoptotic genes and their 
products. A family of proteins, known as the inhibitors of apop-
tosis proteins (IAP), is of particular importance. The IAPs have 
been shown to bind to and inhibit a variety of proapoptotic fac-
tors (e.g., apoptosis-promoting caspases), thereby effectively 
suppressing drug- and radiation-induced apoptosis. The IAPs 
characteristically contain one to three copies of a baculoviral 
IAP repeat (BIR) domain, which plays a crucial role in this 
process.8–11 Some IAPs, including X-linked inhibitor of apop-
tosis protein and survivin, have been reported to have therapeu-
tic potential or prognostic value for lung cancers.12–15
BIRC6 (baculoviral IAP repeat-containing 6) protein is 
a relatively large IAP (528 kDa) containing a single N-terminal 
BIR domain and a unique C-terminal ubiquitin-conjugating 
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(UBC) domain. Similar to other IAPs, it is able to bind 
directly to caspases-3, 6, 7 and 9 and inhibit their activities 
through its BIR domain. In addition to its IAP activity, 
BIRC6 can ubiquitylate the proapoptotic proteins Smac/
Diablo, active caspase-9 and HTRA2/OMI  through its UBC 
domain.16–18 Recent evidence supports a significant role for 
BIRC6 in conferring apoptosis resistance to cancer cells, as 
reported for cell lines derived from human brain and breast 
cancers.19,20 Elevated expression of BIRC6 messenger RNA 
(mRNA) in childhood de novo acute myeloid leukemia has 
been associated with poor patient survival.21,22 However, a role 
for BIRC6 in lung cancer has not yet been established.
In the present study, we assessed the prognostic rele-
vance of BIRC6 in NSCLC by examining the levels of BIRC6 
protein in preserved, surgically resected NSCLC tissues for 
correlations with clinicopathological features and patient out-
comes. We also looked for correlations between BIRC6 pro-
tein expression and chemoresistance, using preserved tissues 
from patient-derived NSCLC tissue xenografts that had been 
evaluated for chemosensitivity. To determine whether BIRC6 
could provide a chemotherapeutic target for NSCLC, the 
effect of BIRC6 knockdown was determined on the growth 
and viability of human lung cancer cell cultures using BIRC6-
targeting small interfering RNA (siRNA) alone and in combi-
nation with an established anticancer drug (cisplatin).
MATERIALS AND METHODS
Materials
Chemicals, solvents and solutions were obtained from 
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada), unless 
otherwise indicated.
Patient Tumor Tissues
Tumor tissues from 78 patients, obtained through sur-
gical resection of primary NSCLCs, had been fixed in 10% 
neutral-buffered formalin and embedded in paraffin blocks 
at the Vancouver General Hospital (2005–2006). None of the 
patients had received preoperative chemo- or radiotherapy. 
The clinical characteristics of the patients, including sex, 
age, histopathology, tumor size, lymph node involvement and 
pathological TNM (pTNM) cancer stage are summarized in 
Table 1. Three-year relapse-free survival data of the patients, 
calculated from the day of surgical resection, were obtained 
from the British Columbia Cancer Agency (BCCA) Cancer 
Registry and from hospital charts at the BCCA. Histologic 
classification of the tumors was based on World Health 
Organization classification. TNM staging was based on the 
staging system proposed by the International Association for 
the Study of Lung Cancer in 2009.23
Patient-Derived NSCLC Xenograft Tissues
Paraffin-embedded tissues of first-generation subrenal 
capsule NSCLC tissue xenografts, derived from 29 patients, 
had been generated in a previous study24 in which the xeno-
grafts were established and evaluated for response to treatment 
with cisplatin plus vinorelbine in vivo (i.e., chemosensitive 
versus chemoresistant). Sections (5-µm thick) were cut from 
all 29 xenograft tissue blocks for immunohistochemical (IHC) 
staining of BIRC6 protein (see below).
IHC Staining and Scoring
Sections of the archival NSCLC tissues were cut on a 
microtome (5 µm thick) and mounted on glass slides. Sections 
were dewaxed in xylene and then hydrated in graded alcoholic 
solutions and distilled water. For histopathologic analysis, rou-
tine hematoxylin and eosin (H&E) staining was carried out. 
For IHC staining, sections were subjected to antigen retrieval 
by boiling it in antigen-unmasking solution for 10 minutes 
(Vector Laboratories Inc., Burlingame, CA). Endogenous per-
oxidase activity was quenched with 3% hydrogen peroxide 
for 10 minutes followed by washing with phosphate-buffered 
saline (PBS [pH 7.4]) and nonspecific binding blocked, using 
SuperBlock blocking buffer (Thermo Scientific, Rockford, 
IL) in Tris-buffered saline (pH 7.4) for 60 min. The sections 
were incubated with rabbit polyclonal anti-BIRC6 antibody 
(Novus Biologicals, Littleton, CO) recognizing epitopes 
between residue 4775 and 4829 (C-terminus) of BIRC6 pro-
tein (Swiss-Prot entry Q9NR09; GeneID 57448) at a 1:100 
dilution at 4°C overnight. Sections were then washed with 
PBS and incubated with goat antirabbit secondary antibodies 
for 30 minutes at room temperature. Sections were washed in 
PBS (five 5-minute washes), and incubated with avidin–biotin 
complex (Vector Laboratories, Foster City, CA) for 30 min-
utes at room temperature. After a further 25-minute washing 
in PBS, immunoreactivity was visualized using 3′, 3′-diami-
nobenzidine in PBS and 3% hydrogen peroxide. Sections were 
counterstained with 5% (w/v) Harris hematoxylin and dehy-
drated in graded alcohols.
Staining of cytoplasm-associated BIRC6 protein was 
evaluated independently by two investigators in blinded anal-
yses. Areas of positive staining were given an intensity score 
of 0, 1, 2, or 3, representing a range from negative staining to 
heavy staining. The percentage of tumor cells showing posi-
tive for a given intensity (percent positive areas, P) was esti-
mated (P1, P2 or P3). Values ranged from 0% to100%. The 
final staining score of each tissue section was determined by 
combining score intensity and percent positive areas using the 
formula: 1×P1 + 2×P2 + 3×P3.25–28
Microdissection and DNA Extraction 
of Patient-Derived First-Generation 
NSCLC Tissue Xenografts
From the paraffin blocks of seven squamous cell 
carcinoma and six adenocarcioma subrenal capsule xenografts, 
23 sections (7-µm thick) were cut, using a microtome, and 
mounted on glass slides. Routine H&E staining was carried 
out on sections 1, 12, and 23. The H&E slides were reviewed 
by pathologists and cancerous areas encircled (>70% cancer 
cells by area). On the basis of the pathological reviews, 
manual microdissection of cancerous areas on sections 2 to 
11 and 13 to 22 was performed using sterile scalpel blades. 
The remaining tissues on the slides were stained with H&E 
to confirm that the microdissection of cancerous areas had 
been carried out correctly. DNA extraction was performed 
according to a standard phenol-chloroform extraction 
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protocol.29 DNA was quantified using a Nanodrop ND1000 
spectrophotometer (Nanodrop Products, Wilmington, DE) 
and verified by gel electrophoresis.
Array Comparative Genomic 
Hybridization and Analysis
For patient-derived subrenal capsule xenografts, genome-
wide copy number analysis was performed using a whole 
genome tiling-path array (the SMRT array v.2) against single 
male reference genomic DNA.30 Fluorescent labeling, hybrid-
ization, scanning, and washing were performed as previously 
described.31–34 Array images were analyzed using SoftWoRx 
Tracker Spot Analysis software (Applied Precision, Issaquah, 
WA) and systematic biases removed using a stepwise normal-
ization algorithm, as previously described.35,36 Normalized 
files were imported into SIGMA2 to combine duplicate spot 
data, display log
2
 signal intensity ratios in relation to genomic 
locations (NCBI Build 36.1), and exclude data points with a 
standard deviation greater than 0.075 and signal to noise ratio 
less than three in either channel.37 Fast Algorithm for Calling 
After Detection of Edges, which uses edge detection in combi-
nation with nonparametric statistics, was used to segment and 
call-filtered log
2
 signal intensity ratio data, using the following 
recommended settings—breakpoints = 2000, amplifications = 
log
2
 signal intensity ratio > 0.8, deletion = log
2
 signal intensity 
ratio < −0.5, 5 level output, p value 0.05, log
2
 ratio delta: 0.1.38 
Copy number data were thus scored as: gain or amplification = 
1, neutral or retention = 0, or loss or deleted = −1, for each indi-
vidual sample. The occurrence of alterations (gain, loss, and 
retention) was then statistically compared between chemoresis-
tant and chemosensitive tumors, using a Fisher exact test, per-
formed in the R statistical computing environment, on a 3 × 2 
contingency table with a p-value threshold of 0.05.34 Adjacent 
regions within 1 Mb, matching direction of copy number dif-
ference and statistical significance, were then merged.
Western Blotting
Cultured cells were lysed using cell lysis buffer (1% 
NP-40, 0.5% sodium deoxycholic acid) supplemented with 
a protease inhibitor cocktail (Roche, Basel, Switzerland); 
total lysate protein was determined using the bicinchoninic 
acid protein assay (Pierce, Rockford, IL). Whole-cell lysates 
(8 μg) were run on a 5% to 12.5% sodium dodecyl sulfate 
polyacrylamide gel at 80 volts for 2.5 hours. The BIRC6 protein 
band (528 kD) was electrotransferred to a polyvinylidene 
fluoride membrane at 25 volts for 3 hours in transfer buffer 
(Tris 25 mM, glycine 191.5 mM, methanol 10%, sodium 
dodecyl sulfate 0.05%) using a semidry transfer apparatus. 
Equal loading of the sample was assessed by separately 
electrotransferring actin (42 kDa) to a polyvinylidene fluoride 
membrane at 100 volts for 1 hour at room temperature with 
transfer buffer (Tris [25 mM], glycine [191.5 mM], methanol 
[15%]), using standard wet transfer apparatus. The membranes 
were then blocked for 1 hour in 5% bovine serum albumin in 
Tris-buffered saline + Tween 20 (0.5 mM Tris-HCl, 45 mM 
NaCl, 0.075% Tween 20 [pH 7.4]). The membranes containing 
the whole-cell lysate proteins were then probed with rabbit 
polyclonal anti-BIRC6 antibody at 1:500 dilution (Novus 
Biologicals, Littleton, CO) and the actin-carrying membranes 
with rabbit antiactin polyclonal antibody at 1:2000 dilution 
overnight at 4°C. Subsequently, the membranes were probed 
with a secondary horseradish peroxidase-conjugated goat 
antirabbit antibody (Thermo Scientific, Rockford, IL). The 
protein bands were detected using SuperSignal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific, Rockford, 
IL). A human prostate cancer cell line, PC3, was used as a 
positive control.
siRNA and Cell Transfection
SiRNA targeting BIRC6 and nontargeting siRNAs were 
purchased from Dharmacon (Lafayette, CO). The BIRC6-
targeting siRNA was sense, 5′-GUU UCA AAG CAG GAU 
GAU G-dTdT-3′.39 Vehicle and nontargeting siRNA (siGE-
NOME nontargeting siRNA #3 D-001210-03-05, Dharmacon) 
were used as controls. To examine the effect of the siRNAs 
on BIRC6 expression, human lung adenocarcinoma cells 
(A549) and squamous cell carcinoma cells (H226), acquired 
from the American Type Culture Collection (Manassas, VA), 
TABLE 1.   BIRC6 Protein Levels in Primary NSCLCs 
(Immunohistochemistry Score)
Clinicopathologic Factors n
BIRC6 Score 
(Mean ± SD) p
Sex
 Male 34 1.35 ± 1.12 0.448
 Female 44 1.12 ± 0.98
Age, yrs
 ≤65 30 1.28 ± 1.06 0.768
 >65 48 1.18 ± 1.04
Pathology
 Adenocarcinoma 49 1.08 ± 0.98 0.566a
  Squamous cell carcinoma 22 1.47 ± 1.17
  Large-cell carcinoma 5 1.4 ± 1.11
 Other subtypes 2 1.5 ± 2.12
Tumor size
 T1 14 1.03 ± 0.27 0.394b
 T2 55 1.29 ± 0.47
 T3 3 0.36 ± 0.56
 T4 6 1.42 ± 0.96
Lymph node involvementc
 N
neg
44 0.99 ± 1.03 0.023
 N
pos
33 1.50 ± 1.02
pTNM stagec
 I 38 0.98 ± 1.04 0.037d
 II 24 1.42 ± 1.04
 III 14 1.40 ± 1.01
 IV 1 2.60
aAdenocarcinoma versus other types.
bT1 versus T2–4.
cInformation of one patient could not be assessed.
dStage I versus stage II–IV.
BIRC6, baculoviral inhibitors of apoptosis proteins repeat-containing 6; pTNM, 
pathological TNM.
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were plated in six-well plates in antibiotic-free Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (FBS; 10%). After 20 hours, the cells were 
transfected with 80 nM siRNA in Lipofectamine 2000 reagent 
(Invitrogen, Burlington, ON, Canada) according to the manu-
facturer’s instructions. Briefly, a complex of Lipofectamine 
2000 and siRNA in Opti-MEM Reduced Serum Media 
(500 μl) was gently added to each well. After 6 hours, the 
transfection mixture was removed and fresh antibiotic-free 
DMEM supplemented with FBS (10%) was added. Vehicle 
(Lipofectamine 2000) and nontargeting siRNA were applied 
in separate wells. Cells were incubated for 24 or 72 hours for 
subsequent Western blotting, measurement of cell viability, or 
treatment with cisplatin.
Treatment of NSCLC Cell Cultures 
with Cisplatin in Combination 
with BIRC6-Targeting siRNA
A549 and H226 cells were transfected with 
Lipofectamine 2000, BIRC6-targeting or nontargeting siR-
NAs for 6 hours, and the transfection medium was replaced 
with fresh antibiotic-free DMEM supplemented with FBS 
(10%) for a 24-hour incubation in 5% carbon dioxide atmo-
sphere. The medium was then replaced by DMEM-10%FBS 
medium containing cisplatin with a final concentration of 20 
µM (A549) or 25 µM (H226) for another 24-hour incuba-
tion. This was followed by a 24-hour incubation in drug-free 
DMEM-10%FBS medium and cell harvesting.
Diphenyltetrazolium Bromide 
Cell Viability Assay
Inhibition of NSCLC cell culture growth was deter-
mined by the 3-(4-, 5-dimethylthiazol-2-yl) 2-, 5-diphenyltet-
razolium bromide (MTT) assay. In brief, 20 µl of MTT (5 mg/
ml) was added to cell cultures in 48-well dishes (cell density: 
103–105 cells/well). Cells were incubated for another 4 hours 
at 37°C in 5% carbon dioxide or air atmosphere before the 
medium was aspirated, and the precipitated formazan was dis-
solved by adding 150 μl of dimethylsulfoxide and incubating 
for 10 to 20 minutes at room temperature. Samples (100 µl) 
were then transferred to 96-well plates. Absorbance was mea-
sured at 570 nm using a microplate reader.
Flow Cytometric Apoptosis Assays
Apoptosis was measured by fluorescence-activated cell 
sorter analysis with annexin-V conjugated with fluorescein iso-
thiocyanate (Annexin-V-FITC) (BD Biosciences PharMingen, 
San Diego, CA) for early apoptosis and 7-amino-actinomycin 
D (7-AAD) for late apoptosis staining according to the manu-
facturer’s protocol. Cells were cultured in DMEM-10% FBS 
medium, treated with BIRC6 siRNA and, subsequently, with 
cisplatin as described above. Twenty-four hours after treatment 
with cisplatin, cells were harvested, washed with cold PBS 
and then resuspended in 1X Binding Buffer (BD Biosciences 
PharMingen) at a concentration of approximately 1 × 106 cells/
ml. Cell suspensions (100 µl; ~1 × 105 cells) were transferred 
to 5-ml culture tubes, and 5-µl Annexin V–FITC and 5-µl 
7-AAD aliquots were added. The cultures were incubated in 
the dark for 15 minutes at 21°C. Annexin–FITC fluorescence 
was measured in the FL1 channel (using a 530/30 band pass 
filter) and 7-AAD in FL3 channel (660/20 BP filter band pass 
filter). Ten thousand events were collected. In the fluorescence-
activated cell sorter graph, nonapoptotic (viable) cells were in 
the lower left quadrant (Q4: AnV−/7AAD−), apoptotic cells in 
the upper and lower right quadrants (Q3: AnV+/7AAD−, early 
apoptotic cells; Q2: AnV+/7AAD+, late apoptotic cells) and 
necrotic cells in the upper left quadrant (Q1: AnV−/7AAD+).
Statistics
The Mann–Whitney U test was used to determine the 
association of BIRC6 protein expression with demographic 
factors. The Kaplan–Meier method was used to estimate curves 
for relapse-free survival for subgroups of BIRC6 expression 
levels and comparisons were made with the use of the log-rank 
test. Hazard ratios were calculated using Cox proportional 
hazard models. The Student’s t test was used for comparison 
of in vitro studies. All tests of significance were two sided, 
and differences were considered statistically significant with 
p values less than 0.05. SPSS software was used for all the 
analyses.
RESULTS
Elevated BIRC6 Protein Expression in 
Clinical NSCLC Samples is Associated 
with Regional Lymph Node Metastasis 
and Advanced pTNM Stages
In a retrospective study, using preserved clinical 
NSCLC samples, correlations were sought between degree 
of BIRC6 protein expression and malignant progression of 
the cancers. As shown in Table 1, the study involved speci-
mens from 78 patients with an average age of 69.09 ± 9.52 
(mean ± SD) years; the majority of the patients had T2 
(70.51%) and N0 (56.41%) status, and 38 (49%) were graded 
as pTNM stage I disease. Immunohistochemical analysis of 
BIRC6 expression was performed on all patients’ NSCLC 
samples and also on nine benign pulmonary parenchymal 
tissues. Benign epithelium cells showed weak to negative 
BIRC6 protein expression (mean ± SD: 0.18 ± 0.29, Fig. 
1A). In contrast, the NSCLC cells showed approximately 
sixfold higher BIRC6 expression with an average score of 
1.21 ± 1.05 (p < 0.001, Fig. 1B–D). Elevated expression 
of BIRC6 protein in the NSCLC samples was associated 
with metastasis to regional lymph nodes (N
neg
 versus N
pos
, 
p = 0.023). Furthermore, there was a significant correlation 
between elevated BIRC6 protein expression and advanced 
pTNM stages (p = 0.037). Since adenocarcinoma and 
squamous cell carcinoma are the major histologic types of 
NSCLCs, the associations of BIRC6 expression with stage 
and lymph node status of these cancers were further deter-
mined. For both types, higher expression levels of BIRC6 
were observed in cancers with lymph node involvement 
and advanced stages, although the increases lacked statis-
tical significance (see Supplemental Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A377).
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Elevated BIRC6 Protein Expression in NSCLCs 
Correlates with Poor Patient Prognosis.
Of the 78 NSCLC samples assessed for BIRC6 expres-
sion, 47.4% scored less than 1, 23.1% scored between 1 and 
less than 2, 21.8% scored between 2 and less than 3, and 
7.7% scored 3 (Fig. 2A). Overall, moderate to strong BIRC6 
expression (score ≥1) was observed in 52.6% of the cases. For 
patient survival analysis, a BIRC6 score = 1 was used to sepa-
rate patients into two groups: score lesser than 1 versus score 
of 1 or more. Kaplan–Meier analysis showed that the group 
with BIRC6 score of 1 or more had markedly lower relapse-
free survival (p = 0.009, Fig. 2B, hazard ratio = 2.458, 95% 
confidence interval [CI]: 1.290–4.683). For adenocarcinoma 
patients, BIRC6 scores of 1 or more were associated with poor 
relapse-free survival (Fig. 2C; p = 0.009, hazard ratio = 2.912, 
95% CI: 1.317–6.441). There was no significant association 
between BIRC6 expression and 3-year relapse-free survival of 
patients with squamous cell carcinoma (Fig. 2D; p = 0.348). 
As shown in Table 2, Cox regression analysis of multivariates, 
consisting of sex, age, histopathologic types, tumor size, lymph 
node status, pTNM stage and BIRC6 score, indicates that ele-
vated BIRC6 expression has a relative risk of 2.099 for 3-year 
relapse-free patient survival (95% CI: 0.992–4.441) with a p = 
0.052. A greater statistical significance (p = 0.030) was obtained 
through Cox regression analysis of only three variables, that is, 
histopathologic types, pTNM stage, and BIRC6 score (Table 3).
Elevated BIRC6 Protein Expression in Patient-
Derived NSCLC Xenografts Associated 
with Increased Chemoresistance.
In a pilot study, patient-derived subrenal capsule cancer 
tissue xenografts of seven lung squamous cell carcinomas and 
six lung adenocarcinomas, showing resistance or sensitivity 
to treatment with cisplatin plus vinorelbine in vivo, were 
subjected to array-based, comparative genomic hybridization. 
As indicated in Table 4, chemoresistant squamous cell 
carcinoma xenografts showed BIRC6 gene copy number gain, 
in contrast to chemosensitive xenografts that did not show 
a change in this parameter. This difference was statistically 
significant using a Fisher exact test (p = 0.029). This finding 
was validated at the protein level by immunohistochemical 
analysis of tissue sections of the xenografts, showing elevated 
BIRC6 protein expression in the chemoresistant xenografts 
except 06L13 (Table 4; Fig. 3A, B) and weak to negative BIRC6 
protein expression in chemosensitive xenografts (Fig. 3C, D). 
An association between BIRC6 gene copy number gain and 
chemoresistance was not observed for lung adenocarcinoma 
xenografts (data not shown).
We next investigated BIRC6 protein expression in tis-
sue sections of first-generation NSCLC xenografts from 29 
patients, including the above seven patients with squamous 
cell carcinomas and six patients with adenocarcinomas, that 
had been assessed for sensitivity to treatment with cisplatin 
plus vinorelbine in vivo. They were distributed into eight che-
mosensitive and 21 chemoresistant xenografts. As shown in 
Figure. 3E, expression of BIRC6 protein was markedly ele-
vated in the chemoresistant xenografts (p = 0.012).
Down-Regulation of the BIRC6 Gene 
Inhibits Proliferation of NSCLC Cells
Five of six NSCLC cell lines showed strong expressions 
of BIRC6 protein as demonstrated by Western blot analysis 
(data not shown). To determine whether targeting the BIRC6 
gene could be used as a potential therapeutic strategy, we 
FIGURE 1.  Immunohistochemical staining of BIRC6 protein in patients’ (A) benign and (B–D), NSCLC tissues. Whereas the 
benign tissue lacked BIRC6 expression (score, A = 0), the NSCLC tissues showed elevated BIRC6 expression with scores B = 1,  
C = 2, and D = 3. NSCLC, non–small-cell lung cancer; BIRC6, baculoviral inhibitors of apoptosis proteins repeat-containing 6.
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tested the effects of siRNA-induced BIRC6 down-regulation 
on A549 cell proliferation. The gene silencing efficacy of 
BIRC6 siRNA was confirmed by Western blotting. After 
transfection of A549 cells with BIRC6 siRNA (80 nM/6 
hour) and subsequent culturing, there was a decrease in the 
amount of cellular BIRC6 protein at 48 hours and essen-
tially no BIRC6 protein at 72 hours, compared with trans-
fection with Lipofectamine only, or nontargeting siRNA 
(Fig. 4A). The proliferation of BIRC6 siRNA-transfected 
A549 cells was determined using an MTT assay. As shown 
in Figure 4B, transfected A549 cultures showed decreased 
growth starting at 48 hours after transfection, resulting in a 
28% lower cell number at 96 hours relative to controls, that 
is, cells treated with Lipofectamine only or nontargeting 
FIGURE 2.  Correlation between elevated BIRC6 expression in resected NSCLCs and poorer 3-year relapse-free survival of 
patients. A, Percentage of NSCLC patients at increasing BIRC6 scores. B, Kaplan–Meier analysis of relapse-free survival of 78 
patients grouped on the basis of BIRC6 scores of their resected tumors (BIRC6 score <1 versus score ≥1, log-rank p =0.009. Hazard 
Ratio=2.458; 95% CI 1.290–4.683). C, Kaplan–Meier analysis of relapse-free survival of 49 patients with resected adenocarcinoma 
(BIRC6 score <1 versus score ≥1, log-rank p =0.009. Hazard Ratio=2.912; 95% CI 1.317–6.441). D, Kaplan–Meier analysis of 
relapse-free survival of 22 patients with resected squamous cell carcinoma (BIRC6 score <1 vs. score ≥1, log-rank p =0.348). BIRC6, 
baculoviral inhibitors of apoptosis proteins repeat-containing 6;NSCLC, non–small-cell lung cancer; CI, confidence interval.
TABLE 2.  Multivariate Cox Regression Analysis of Relapse-
Free Survival of NSCLC Patients
Variables
Relative  
Risk 95% CI p
Sex
 Female vs. male 1.175 0.53–2.606 0.692
Age, yrs
<65 vs. ≥65 1.344 0.654–2.766 0.421
Histopathologic types
Adenocarcinoma vs. other 0.601 0.296–1.345 0.215
Tumor size
T1 vs. T2–T4 1.406 0.488–4.056 0.528
Lymph node status
N
neg
 vs. N
pos
0.785 0.243–2.536 0.686
pTNM stage
Stage I vs. stage II–IV 4.744 1.328–16.946 0.017
BIRC6 score
<1 vs. ≥1 2.099 0.992–4.441 0.052
Cox regression analysis using seven variables.
CI, confidence interval; NSCLC, non–small-cell lung cancer; BIRC6, baculoviral 
inhibitors of apoptosis proteins repeat-containing 6.
TABLE 3.  Multivariate Cox Regression Analysis of Relapse-
Free Survival of NSCLC Patients
Variables
Relative  
Risk 95% CI p
Histopathologic types
 Adenocarcinoma vs. other 0.646 0.322–1.2985 0.222
pTNM stage
Stage I vs. stage II–IV 2.567 1.277–5.167 0.009
BIRC6 score
<1 vs. ≥1 2.233 1.083–4.604 0.030
Cox regression analysis using three variables.
CI, confidence interval; pTNM, pathological TNM; BIRC6, baculoviral inhibitors of 
apoptosis proteins repeat-containing 6.
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siRNA (p < 0.001). Similar results were obtained using a 
squamous cell carcinoma cell line, H226 (see Supplemental 
Fig. 1A, Supplemental Digital Content 1, http://links.lww.
com/JTO/A377). 
Effect of Down-Regulating BIRC6 Expression 
on Apoptosis of NSCLC Cells: Enhancement 
of Cisplatin-Induced Apoptosis
To investigate the effect of BIRC6 down-regulation on 
apoptosis, A549 cells were transfected with BIRC6 siRNA 
(80 nM/6 hours), Lipofectamine or nontargeting siRNA 
and incubated for 48 hours. Apoptotic cells were detected 
through flow cytometric analysis of annexin V or 7-AAD 
stained cells. As shown in Figure 4C-E,  BIRC6 siRNA did 
not significantly increase apoptosis compared with controls 
(p > 0.05).
To investigate whether down-regulation of BIRC6 
expression has the potential to sensitize lung cancer cells to 
chemotherapy, three groups of A549 cell cultures, that is, 
TABLE 4.  Gains in BIRC6 DNA Copy Number and Elevated 
Scores of BIRC6 Protein in Patient-Derived Subrenal Capsule 
Lung Squamous Cell Carcinoma Xenografts Resistant to 
Treatment with Cisplatin Plus Vinorelbine
Case
DNA Copy 
Number  
Change
BIRC6  
Protein  
(IHC Score)
Average  
IHC Score  
(Mean ± SD)
Chemoresistant 2.02 ± 0.79
 05L48 Gain 3.0
 06L13 Gain 0.7
 05L1 Gain 2.3
Chemosensitive 0.15 ± 0.23
 L7 None 0
 05L8 None 0.01
 05L42 None 0.25
 06L28 None 0
BIRC6, baculoviral inhibitors of apoptosis proteins repeat-containing 6; IHC, 
immunohistochemistry.
FIGURE 3.  Patient-derived subrenal capsule NSCLC tissue xenografts resistant to treatment with cisplatin + vinorelbine (A, B) 
showed strong IHC staining (brown) of BIRC6 protein, compared with a sensitive xenograft (C, D). Arrows point at the renal 
capsules of the hosts (×200). E, Shows significant difference in BIRC6 IHC score between chemosensitive and chemoresistant 
xenografts (p = 0.012). NSCLC, non–small-cell lung cancer; IHC, immunohistochemistry. BIRC6, baculoviral inhibitors of apop-
tosis proteins repeat-containing 6.
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pretreated with BIRC6 siRNA, Lipofectamine, or nontarget-
ing siRNA controls, were incubated with cisplatin to trigger 
apoptosis. As shown in Figure 4F–H, BIRC6 siRNA markedly 
increased cisplatin-induced apoptosis of A549 lung adenocar-
cinoma cells compared with controls (p = 0.03 in each case). 
Similar results were obtained using a squamous cell carcinoma 
cell line, H226 (see Supplemental Fig. 1B–D, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A377).
DISCUSSION
NSCLC is an aggressive disease characterized by rapid 
progression and very poor patient survival. The majority of 
NSCLCs exhibit high resistance to conventional first-line 
chemotherapy.5 Prognostic factors for NSCLC progression 
and more effective therapies are, therefore, critically needed 
for improved management of the disease. The present study 
focused on BIRC6 protein, a member of the IAP family 
FIGURE 4. A, Western blot analysis confirming the gene silencing efficacy of BIRC6 siRNA. After transfection of A549  
cells with BIRC6 siRNA (80 nM/6 hrs) and subsequent culturing, there was a substantial decrease in the amount of cellu-
lar BIRC6 protein, especially at 72 hours, compared with cells transfected with Lipofectamine only (Lipo) or nontargeting 
siRNA. B, MTT assay showed that transfection with BIRC6 siRNA (80 nM/6 hrs) led to a decrease in the proliferation of A549 
cells within 96 hours, compared with controls (Lipo or NT) (p < 0.001). C–E, Apoptosis of A549 cells transfected with (C) 
Lipo, (D) NT, or (E), BIRC6 siRNA (80 nM/ 6 hrs) and subsequently incubated for 48 hours, as assessed by flow cytometric 
analysis of Annexin V/7-aminoactinomycin D stained cells. On the basis of Q2+Q3 values (apoptotic cell populations),  
BIRC6 siRNA slightly increased apoptosis compared with controls, but without statistical significance. (F–H), A549 cells were 
transfected with (F) Lipo, (G) NT, or (H) BIRC6 siRNA (80 nM/6 hrs), incubated for 24 hours, and subsequently treated with 
20 µM cisplatin for another 24 hours. BIRC6 siRNA markedly enhanced cisplatin-induced apoptosis of A549 cells  
compared with Lipo (p = 0.034) or NT (p = 0.030). (Data are representative of 3 independent experiments). BIRC6,  
baculoviral inhibitors of apoptosis proteins repeat-containing 6; siRNA, small interfering  RNA; MTT, diphenyltetrazolium 
bromide assay.
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thought to play an important role in the malignant progres-
sion and chemoresistance of cancers.40–43 Although the clini-
cal relevance of BIRC6 remains largely unknown, elevated 
expression of BIRC6 mRNA or protein has been detected in 
a number of cancers.21,22,44,45 In the case of childhood acute 
leukemia, elevated expression of BIRC6-mRNA was found to 
be associated with poor relapse-free patient survival.21,45 This 
is consistent with the correlation found in the present study 
between elevated BIRC6 protein expression and poor 3-year 
relapse-free survival of patients with resectable NSCLCs 
(Fig. 2B), indicating the potential for elevated BIRC6 protein 
expression to be used as a poor prognostic factor for patients 
with NSCLC. As indicated by Cox regression analysis of 
seven variates (Table 2), elevated BIRC6 expression may have 
independent prognostic value with a p = 0.052. This borderline 
significance could be a result of the relatively small number of 
samples (n = 78) used. A Cox regression analysis of only his-
tologic type, stage, and BIRC6 score shows much higher sig-
nificance for BIRC6 score (p = 0.030, Table 3). Notably, 49% 
of the cases in this study were at stage I. Patients with stage I 
NSCLCs in general have an estimated 28% to 45% chance of 
recurrence. If the patients who are likely to have recurrences 
after surgery could be identified, postoperative adjuvant che-
motherapy could be recommended. Elevated BIRC6 protein 
expression could potentially serve as a marker for identify-
ing stage I NSCLC patients with increased risk of postopera-
tive relapse who would likely benefit from adjuvant therapy. 
However, in the current study, the number of patients with 
stage I NSCLC receiving adjuvant therapy was rather small to 
properly validate this suggestion (n = 10; all were relapse-free 
upon 3-year follow-up; data not shown).
The elevated expressions of BIRC6 protein in pTNM 
stages II–IV, relative to pTNM stage I, and in cases of lymph 
node involvement (Table 1, Fig. 2A) suggest that BIRC6 pro-
tein is involved in the malignant progression of NSCLC. The 
findings are echoed by those reported in the case of childhood 
acute leukemia, where the median level of BIRC6 expression 
was significantly increased in patients with extramedullary 
involvement.45
Molecular mechanisms underlying the chemoresis-
tance of NSCLC can be studied with patient-derived, sub-
renal capsule NSCLC tissue xenograft models that closely 
resemble the disease in the clinic.24 Chemoresistance of such 
xenografts was found to be associated with elevated BIRC6 
protein expression and BIRC6 copy number gains (Fig. 3, 
Table 4), suggesting that BIRC6 plays a role in conferring che-
moresistance to NSCLCs and that its expression may be driven 
at the level of gene dosage. This is in agreement with a role 
for BIRC6 in chemoresistance reported for other cancer types 
where elevated expression of BIRC6 protein has been linked 
to poor chemoresponse in childhood leukemia,21,45 and down-
regulation of BIRC6 expression increased sensitivity of vari-
ous types of cancer cells to conventional anticancer drugs.19,46,47 
Elevated BIRC6 protein, therefore, represents a promising pre-
dictive marker for chemoresistance of NSCLCs. The disparity 
between BIRC6 copy number and intensity of IHC staining 
observed in the 06L13 xenograft (Table 4) could be a result 
of alterations of BIRC6 expression at the epigenetic level, for 
example by chromosomal methylation or histone acetylation.48
The present study also provides preliminary evidence 
suggesting that targeted inhibition of BIRC6 may represent a 
novel potential target for NSCLC therapy, as indicated by the 
inhibition of NSCLC cell proliferation resulting from siRNA-
induced down-regulation of BIRC6 (Fig. 4B, Supplemental 
Fig. 1A, Supplemental Digital Content 1, http://links.lww.
com/JTO/A377). Furthermore, down-regulation of BIRC6 
led to sensitization of NSCLC cells to cisplatin, as shown by 
increased apoptosis (Fig. 4F-H, Supplemental Fig. 1, B–D, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A377). Similar chemosensitizing effects of BIRC6 down-
regulation have been reported for other types of cancer.17,46 
This suggests that down-regulation of the BIRC6 gene as 
a therapeutic approach may be especially effective in com-
bination with conventional chemotherapeutics. However, 
given the diverse mechanisms underlying anticancer effects 
of conventional chemotherapeutic drugs, more studies are 
needed to validate this effect and determine the most effective 
combinations.
In conclusion, the present study suggests that BIRC6 
may play an important role in the malignant progression and 
chemoresistance of NSCLC, and that its elevated expression 
provides a novel and potentially useful predictive marker for 
chemoresistance and poor prognosis for NSCLC patients. 
BIRC6 may also provide a potentially effective therapeutic 
target for chemosensitization and treatment of NSCLC.
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